Division of Hepatology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Arizona State University, Mayo Clinic, Phoenix, Arizona, USA.
Am J Gastroenterol. 2018 Jan;113(1):56-57. doi: 10.1038/ajg.2017.432.
Approximately one-third of patients with primary biliary cholangitis (PBC) fail to respond to ursodeoxycholic acid (UDCA) and are at risk for progression to biliary cirrhosis and end-stage liver disease. In this paper by Pares et al., the authors evaluate the effect of long-term use of bezafibrate in patients with primary biliary cholangitis (PBC) and inadequate response to UDCA. They found that addition of bezafibrate led to normalization of serum alkaline phosphatase in half of the study subjects and major improvement in pruritus. Here we discuss these findings and place them in context with current knowledge about fibrates in PBC.
大约三分之一的原发性胆汁性胆管炎（PBC）患者对熊去氧胆酸（UDCA）治疗无应答，并且有进展为胆汁性肝硬化和终末期肝病的风险。在 Pares 等人的这篇论文中，作者评估了长期使用苯扎贝特治疗对 UDCA 治疗应答不足的原发性胆汁性胆管炎（PBC）患者的效果。他们发现，苯扎贝特的添加使一半的研究对象的血清碱性磷酸酶恢复正常，并显著改善瘙痒。在这里，我们讨论这些发现，并将其与目前关于 PBC 中纤维酸酯的知识联系起来。
